Lexicon Pharmaceuticals, Inc
(NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the t...

Website: http://www.lexpharma.com

Founded: 1995

Full Time Employees: 184

Sector: Healthcare

Industry: Biotechnology

Pharmaceuticals

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-07-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30

revenues:
net product revenue	1,090,000	1,055,000	1,008,000	1,322,000	1,262,000	1,550,000	1,741,000	1,617,000	1,093,000	672,000	148,000	291,000											6,542,000	8,985,000	7,877,000	8,568,000	8,351,000	8,672,000	6,740,000	7,521,000	6,286,000	7,316,000	5,460,000	5,447,000	5,830,000	3,892,000	721,000
licensing and milestone revenue	20,000,000
royalties and other revenue	12,000	136,000	20,000			4,000	9,000	30,000	37,000	30,000	14,000	26,000	24,000	28,000	39,000	35,000	37,000	14,000	23,000	234,000	27,000	199,000	92,000	153,000	114,000	137,000	187,000	150,000	37,000	71,000	124,000	78,000	82,000
total revenues	21,102,000	5,493,000	14,182,000	28,866,000	1,262,000	26,554,000	1,750,000	1,647,000	1,130,000	702,000	162,000	317,000						14,000	23,000	234,000	27,000	199,000	6,634,000	9,163,000	7,999,000	8,727,000	294,448,000	9,682,000	9,216,000	17,393,000	6,856,000	13,753,000	25,207,000	33,047,000	26,942,000	12,053,000	18,293,000	23,037,000	27,717,000	20,089,000		127,280,000	566,000	376,000	1,792,000	21,482,000	419,000	676,000	277,000	1,410,000	238,000	214,000	360,000	218,000	372,000	199,000	300,000	343,000	355,000	555,000	596,000	1,253,000	781,000	1,233,000	1,641,000	2,322,000	2,131,000	2,989,000	4,168,000	6,492,750	7,512,000	9,566,000	8,893,000	9,077,500	10,167,000	12,648,000	13,495,000	16,066,000	19,613,000	16,164,000
yoy	1572.11%	-79.31%	710.40%	1652.64%	11.68%	3682.62%	980.25%	419.56%										-92.96%	-99.65%	-97.45%	-99.66%	-97.72%	-97.75%	-5.36%	-13.21%	-49.82%	4194.75%	-29.60%	-63.44%	-47.37%	-74.55%	14.10%	37.80%	43.45%	-2.80%	-40.00%		-81.90%	4797.00%	5242.82%		492.50%	35.08%	-44.38%	546.93%	1423.55%	76.05%	215.89%	-23.06%	546.79%	-36.02%	7.54%	20.00%	-36.44%	4.79%	-64.14%	-49.66%	-72.63%	-54.55%	-54.99%	-63.68%	-46.04%	-63.35%	-58.75%	-60.63%	-64.24%	-71.63%	-68.75%	-53.13%	-28.47%	-26.11%	-24.37%	-34.10%	-43.50%	-48.16%	-21.75%
qoq	284.16%	-61.27%	-50.87%	2187.32%	-95.25%	1417.37%	6.25%	45.75%	60.97%	333.33%	-48.90%							-39.13%	-90.17%	766.67%	-86.43%	-97.00%	-27.60%	14.55%	-8.34%	-97.04%	2941.19%	5.06%	-47.01%	153.69%	-50.15%	-45.44%	-23.72%	22.66%	123.53%	-34.11%	-20.59%	-16.88%	37.97%			22387.63%	50.53%	-79.02%	-91.66%	5026.97%	-38.02%	144.04%	-80.35%	492.44%	11.21%	-40.56%	65.14%	-41.40%	86.93%	-33.67%	-12.54%	-3.38%	-36.04%	-6.88%	-52.43%	60.44%	-36.66%	-24.86%	-29.33%	8.96%	-28.71%	-28.29%	-35.81%	-13.57%	-21.47%	7.57%	-2.03%	-10.72%	-19.62%	-6.28%	-16.00%	-18.08%	21.34%
operating expenses:
cost of sales	108,000	201,000	10,000	33,000	30,000	348,000	71,000	166,000	31,000	70,000	7,000	8,000											633,000	728,000	568,000	774,000	577,000	1,327,000	553,000	569,000	551,000	838,000	533,000	538,000	599,000	537,000	225,000
research and development, including stock-based compensation of 1,369 and 1,574, respectively	12,756,000
selling, general and administrative, including stock-based compensation of 1,709 and 1,469	9,234,000
total operating expenses	22,098,000	20,273,000	26,369,000	25,130,000	26,941,000	59,291,000	65,443,000	57,001,000	46,463,000	47,439,000	49,793,000	44,557,000	31,166,000	30,306,000	23,134,000	24,042,000	23,417,000	25,344,000	22,985,000	18,193,000	20,866,000	7,424,000	52,777,000	73,742,000	70,437,000	55,944,000	69,772,000	28,227,000	26,685,000	29,234,000	29,899,000	44,182,000	63,173,000	63,832,000	56,460,000	45,946,000	60,778,000	54,367,000	62,650,000	57,110,000	46,365,000	38,920,000	34,243,000	27,064,000	28,319,000	24,929,000	40,755,000	26,787,000	30,749,000	18,386,000	31,454,000	28,838,000	25,915,000	24,710,000	29,432,000	25,679,000	29,683,000	33,685,000	26,046,000	26,481,000	29,732,000	23,678,000	25,034,000	25,307,000	26,607,000	23,259,000	23,888,000	25,771,000	27,738,000	27,239,000	32,334,000	35,952,000	33,331,000	32,275,000	29,609,000	30,598,000	32,590,000	30,638,000	32,319,000	33,097,000
income from operations	-996,000	-14,780,000	-12,187,000	3,736,000	-25,679,000	-32,737,000	-63,693,000	-55,354,000	-45,333,000	-46,737,000	-49,631,000	-44,240,000	-31,142,000	-30,278,000	-23,095,000	-24,007,000	-23,380,000	-25,330,000	-22,962,000	-17,959,000	-20,839,000	-7,458,000	86,675,000	-64,579,000	-62,438,000	-47,217,000	224,676,000	-18,545,000	-17,469,000	-11,841,000	-23,043,000	-30,429,000	-37,966,000	-30,785,000	-29,518,000	-33,893,000	-42,485,000	-31,330,000	-34,933,000	-37,021,000	-33,871,000	88,360,000	-33,677,000	-26,688,000	-26,527,000	-3,447,000	-40,336,000	-26,111,000	-30,472,000	-16,976,000	-31,216,000	-28,624,000	-25,555,000	-24,492,000	-29,060,000	-25,480,000	-29,383,000	-33,342,000	-25,691,000	-25,926,000	-29,136,000	-22,425,000	-24,253,000	-24,074,000	-24,966,000	-21,847,000	-21,757,000	-22,782,000	-23,570,000	-20,889,000	-24,822,000	-26,386,000	-24,438,000	-18,467,000	-19,442,000	-17,950,000	-19,095,000	-14,572,000	-12,706,000	-16,933,000
yoy	-96.12%	-54.85%	-80.87%	-106.75%	-43.35%	-29.95%	28.33%	25.12%	45.57%	54.36%	114.90%	84.28%	33.20%	19.53%	0.58%	33.68%	12.19%	239.64%	-126.49%	-72.19%	-66.62%	-84.20%	-61.42%	248.23%	257.42%	298.76%	-1075.03%	-39.05%	-53.99%	-61.54%	-21.94%	-10.22%	-10.64%	-1.74%	-15.50%	-8.45%	25.43%	-135.46%	3.73%	38.72%	27.69%	-2663.39%	-16.51%	2.21%	-12.95%	-79.69%	29.22%	-8.78%	19.24%	-30.69%	7.42%	12.34%	-13.03%	-26.54%	13.11%	-1.72%	0.85%	48.68%	5.93%	7.69%	16.70%	2.65%	11.47%	5.67%	5.92%	4.59%	-12.35%	-13.66%	-3.55%	13.12%	27.67%	47.00%	27.98%	26.73%	53.01%	6.01%
qoq	-93.26%	21.28%	-426.20%	-114.55%	-21.56%	-48.60%	15.06%	22.11%	-3.00%	-5.83%	12.19%	42.06%	2.85%	31.10%	-3.80%	2.68%	-7.70%	10.31%	27.86%	-13.82%	179.42%	-108.60%	-234.22%	3.43%	32.24%	-121.02%	-1311.52%	6.16%	47.53%	-48.61%	-24.27%	-19.85%	23.33%	4.29%	-12.91%	-20.22%	35.60%	-10.31%	-5.64%	9.30%	-138.33%	-362.37%	26.19%	0.61%	669.57%	-91.45%	54.48%	-14.31%	79.50%	-45.62%	9.06%	12.01%	4.34%	-15.72%	14.05%	-13.28%	-11.87%	29.78%	-0.91%	-11.02%	29.93%	-7.54%	0.74%	-3.57%	14.28%	0.41%	-4.50%	-3.34%	12.83%	-15.84%	-5.93%	7.97%	32.33%	-5.01%	8.31%	-6.00%	31.04%	14.69%	-24.96%
operating margin %	-4.72%	-269.07%	-85.93%	12.94%	-2034.79%	-123.28%	-3639.60%	-3360.90%	-4011.77%	-6657.69%	-30636.42%	-13955.84%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-180928.57%	-99834.78%	-7674.79%	-77181.48%	-3747.74%	1306.53%	-704.78%	-780.57%	-541.05%	76.30%	-191.54%	-189.55%	-68.08%	-336.10%	-221.25%	-150.62%	-93.16%	-109.56%	-281.20%	-232.25%	-136.00%	-126.03%	-184.28%	-Infinity%	69.42%	-5950.00%	-7097.87%	-1480.30%	-16.05%	-9626.73%	-3862.57%	-11000.72%	-1203.97%	-13115.97%	-13375.70%	-7098.61%	-11234.86%	-7811.83%	-12804.02%	-9794.33%	-9720.70%	-7236.90%	-4671.35%	-4888.59%	-1789.70%	-3105.38%	-1952.47%	-1521.39%	-940.87%	-1020.98%	-762.19%	-565.50%	-321.73%	-330.43%	-275.83%	-274.80%	-203.44%	-191.23%	-141.92%	-141.50%	-90.70%	-64.78%	-104.76%
interest and other expense	-1,590,000	-2,031,000	-2,155,000	-2,318,000	-1,835,000	-3,858,000	-4,562,000	-2,211,000	-4,948,000
interest income and other	1,543,000	1,281,000	1,573,000	1,834,000	2,219,000	2,829,000	3,444,000	4,136,000	1,884,000
net income	-1,043,000	-15,530,000	-12,769,000	3,252,000	-25,295,000	-33,766,000	-64,811,000	-53,429,000	-48,397,000	-49,756,000	-50,525,000	-44,904,000	-31,934,000	-30,494,000	-23,387,000	-24,587,000	-23,476,000	-25,611,000	-23,122,000	-18,067,000	-20,958,000	-5,495,000	82,603,000	-69,071,000	-66,611,000	-51,138,000	226,086,000	-23,018,000	-21,797,000	-16,255,000	-27,512,000	-34,706,000	-42,075,000	-25,168,000	-30,722,000	-35,059,000	-34,891,000	-27,252,500	-36,015,000	-38,112,000	-34,883,000																													-15,417,000	-23,459,000	-20,034,000	-17,950,000	-12,177,000	-14,111,000	-13,591,000	-18,915,000	-13,823,000	-12,755,000	-16,902,000
yoy	-95.88%	-54.01%	-80.30%	-106.09%	-47.73%	-32.14%	28.28%	18.98%	51.55%	63.17%	116.04%	82.63%	36.03%	19.07%	1.15%	36.09%	12.01%	366.08%	-127.99%	-73.84%	-68.54%	-89.25%	-63.46%	200.07%	205.60%	214.60%	-921.77%	-33.68%	-48.19%	-35.41%	-10.45%	-1.01%	20.59%	-7.65%	-14.70%	-8.01%	0.02%																																	26.61%	66.25%	47.41%	-5.10%	-11.91%	10.63%	-19.59%
qoq	-93.28%	21.62%	-492.65%	-112.86%	-25.09%	-47.90%	21.30%	10.40%	-2.73%	-1.52%	12.52%	40.62%	4.72%	30.39%	-4.88%	4.73%	-8.34%	10.76%	27.98%	-13.79%	281.40%	-106.65%	-219.59%	3.69%	30.26%	-122.62%	-1082.21%	5.60%	34.09%	-40.92%	-20.73%	-17.51%	67.18%	-18.08%	-12.37%	0.48%	28.03%	-24.33%	-5.50%	9.26%																														-34.28%	17.10%	11.61%	47.41%	-13.71%	3.83%	-28.15%	36.84%	8.37%	-24.54%
net income margin %	-4.94%	-282.72%	-90.04%	11.27%	-2004.36%	-127.16%	-3703.49%	-3244.02%	-4282.92%	-7087.75%	-31188.27%	-14165.30%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-182935.71%	-100530.43%	-7720.94%	-77622.22%	-2761.31%	1245.15%	-753.80%	-832.74%	-585.97%	76.78%	-237.74%	-236.51%	-93.46%	-401.28%	-252.35%	-166.92%	-76.16%	-114.03%	-290.87%	-190.73%	-118.30%	-129.94%	-189.72%	-Infinity%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	-237.45%	-312.29%	-209.43%	-201.84%	-134.14%	-138.79%	-107.46%	-140.16%	-86.04%	-65.03%	-104.57%
net loss per common share, basic and diluted		-40	-40		-70	-90	-180	-170	-200	-200	-210	-220	-170	-170	-130	-160	-160			-130	-150			-650	-630			-220	-210	-150	-260	-330	-400	-240	-290	-330	-330	-262.5	-350	-370	-340																													-110	-170	-150	-130	-60	-140	-170	-240	-180	-200	-260
weighted-average common shares outstanding, basic and diluted	400,240,000	363,053,000	363,399,000		362,073,000	320,031,000	361,492,000	310,836,000
other comprehensive loss:
unrealized loss on investments	-160,000			-39,000	-94,000																												-172,000
comprehensive loss	-1,203,000	-15,529,000	-12,726,000		-25,389,000	-33,996,000	-64,269,000	-53,572,000	-48,478,000	-49,612,000	-50,538,000	-44,841,000	-31,669,000	-30,431,000	-23,728,000	-24,700,000	-23,503,000			-18,077,000	-20,947,000			-69,619,000	-65,835,000			-22,965,000	-21,752,000	-16,196,000	-27,365,000	-34,531,000	-42,247,000	-28,537,000	-30,571,000	-35,009,000	-34,960,000	-32,692,000	-36,273,000	-38,073,000	-34,367,000	86,473,000	-35,322,000	-27,999,000	-27,990,000	-2,998,000	-40,501,000	-26,033,000	-30,827,000	-17,450,000	-31,651,000	-29,091,000	-25,955,000	-24,871,000	-29,498,000	-25,894,000	-29,946,000
licensing revenue		4,302,000	13,154,000	27,544,000
research and development, including stock-based compensation of 1,832, 1,460, 5,026 and 4,733, respectively		12,451,500	18,757,000
selling, general and administrative, including stock-based compensation of 1,612, 1,341, 4,656 and 7,229 respectively		7,140,500	7,602,000
other comprehensive income:
unrealized gain on investments		1,000	43,000			-230,000	542,000	-143,000	-81,000	144,000	-13,000	63,000	265,000	-120,250	-341,000	-113,000	-27,000	-5,000		-10,000	11,000	-41,000	-277,000	-548,000	776,000	48,000	-50,000	53,000	45,000	59,000	147,000	175,000		-159,000	151,000	50,000	-69,000	-273,000	-258,000	39,000	516,000	30,250	-40,000	75,000	86,000		-3,000	-5,000	8,000	-36,000	7,000	-11,000	19,000		41,000	37,000	-78,000
research and development, including stock-based compensation of 1,620, 1,679, 3,194 and 3,273, respectively				15,747,000
selling, general and administrative, including stock-based compensation of 1,575, 3,180, 3,044 and 5,888 respectively				9,350,000
net income per common share, basic				10														-170	-160			-30	770			-480	2,130
net income per common share, diluted				10														-170	-160			-30	710			-430	1,950
weighted-average common shares outstanding, basic				363,294,000
weighted-average common shares outstanding, diluted				363,570,000
comprehensive income				3,213,000														-25,616,000	-23,122,000			-5,536,000	82,326,000			-51,090,000	226,036,000
research and development, including stock-based compensation of 1,574 and 1,594, respectively					15,303,000
selling, general and administrative, including stock-based compensation of 1,469 and 2,708, respectively					11,608,000
research and development, including stock-based compensation of 1,460, 1,337, 4,733, and 3,842, respectively						14,448,750	25,780,000
selling, general and administrative, including stock-based compensation of 1,341, 2,561, 7,229, and 7,286, respectively						27,711,000	39,592,000
research and development, including stock-based compensation of 1,679, 1,302, 3,273, and 2,505, respectively								17,643,000
selling, general and administrative, including stock-based compensation of 3,180, 2,513, 5,888, and 4,725, respectively								39,192,000
research and development, including stock-based compensation of 1,594 and 1,203, respectively									14,372,000
selling, general and administrative, including stock-based compensation of 2,708 and 2,212, respectively									32,060,000
shares used in computing net loss per common share, basic and diluted									245,390,000	8,018,000	244,925,000	204,783,000	189,014,000	7,749,000	174,904,000	149,616,000	149,150,000			144,451,000	143,379,000			107,073,000	106,536,000			106,272,000	106,054,000	30,000	105,881,000	105,848,000	105,668,000	26,279,750	105,582,000																																			1,000	136,796,000	136,796,000	136,795,000	12,467,000	104,196,000	79,568,000	77,938,000	2,200,000	64,832,000	64,627,000
research and development, including stock-based compensation of 1,337, 939, 3,842 and 3,069, respectively										11,031,250	17,558,000
selling, general and administrative, including stock-based compensation of 2,561, 1,709, 7,286, and 5,183, respectively										20,343,750	32,228,000
interest expense										-1,920,000	-3,899,000	-1,960,000	-1,821,000	-1,103,000	-864,000	-703,000	-110,000	-295,000	-171,000	-169,000	-167,000	-170,000	-4,118,000	-5,125,000	-5,131,000	-5,191,000	-5,204,000	-5,164,000	-5,117,000	-5,224,000	-5,252,000	-5,187,000	-5,114,000	-2,163,000	-1,619,000	-1,614,000	-1,588,000	-1,634,000	-1,646,000	-1,638,000	-1,649,000	-1,678,000	-1,687,000	-1,655,000	-1,702,000	-892,000	-449,000	-455,000	-457,000	-477,000	-492,000	-496,000	-506,000	-520,000	-527,000	-530,000	-537,000	-551,000	-560,000	-810,000	-607,000	-626,000	-637,000	-729,000	-727,000	-545,000	-785,000	-729,000	-666,000	-505,000	-675,000	-675,000	-670,000	-519,250	-694,000	-695,000	-688,000	-816,000	-817,000	-813,000
interest and other income										1,332,500	3,005,000	1,296,000	1,029,000	887,000	572,000	123,000	14,000	14,000	11,000	61,000	48,000	875,000	301,000	633,000	958,000	1,270,000	600,000	691,000	789,000	810,000	783,000	910,000	1,005,000	561,000	415,000	448,000	530,000	545,000	564,000	547,000	637,000	68,000	82,000	269,000	153,000
research and development, including stock-based compensation of 1,302, 1,098, 2,505 and 2,130, respectively												14,541,000
selling, general and administrative, including stock-based compensation of 2,513, 1,734, 4,725, and 3,474, respectively												30,008,000
research and development, including stock-based compensation of 1,203 and 1,032, respectively													12,026,000
selling, general and administrative, including stock-based compensation of 2,212 and 1,740, respectively													19,140,000
research and development, including stock-based compensation of 939, 1,138, 3,069 and 3,608 respectively														9,709,750	10,557,000
selling, general and administrative, including stock-based compensation of 1,709, 1,574, 5,183 and 4,741 respectively														7,938,500	12,577,000
research and development, including stock-based compensation of 1,098, 1,184, 2,130 and 2,470 respectively																13,356,000
selling, general and administrative, including stock-based compensation of 1,734, 1,602, 3,474 and 3,167 respectively																10,686,000
research and development, including stock-based compensation of 1,032, and 1,286, respectively																	14,926,000
selling, general and administrative, including stock-based compensation of 1,740, and 1,565, respectively																	8,491,000
collaborative agreements																								25,000	8,000	22,000	285,910,000	860,000	2,439,000	9,801,000	446,000	6,359,000	19,665,000	27,486,000	21,112,000	8,104,000	17,565,000	23,001,000	27,686,000	20,001,000		127,093,000	505,000	338,000	1,792,000
research and development, including stock-based compensation of 1,138, 1,029, 3,608 and 5,154, respectively																		9,637,000	15,682,000
selling, general and administrative, including stock-based compensation of 1,574, 875, 4,741 and 5,440, respectively																		5,874,000	7,303,000
impairment loss on buildings																								1,600,000																		1,248,000	2,349,000				13,102,000
other operating income:
gain on sale of xermelo																						-233,000	132,818,000
loss on debt extinguishments																						-63,750	-255,000
shares used in computing net income per common share, basic																		1,094,000	145,820,000			3,867,000	107,309,000			18,000	106,272,000
shares used in computing net income per common share, diluted																		1,094,000	145,820,000			3,867,000	117,552,000			5,000	116,640,000
research and development, including stock-based compensation of 1,184, 1,949, 2,470 and 4,125, respectively																				10,257,000
selling, general and administrative, including stock-based compensation of 1,602, 2,309, 3,167 and 4,565, respectively																				7,936,000
research and development, including stock-based compensation of 1,286 and 2,176, respectively																					12,609,000
selling, general and administrative, including stock-based compensation of 1,565, and 2,256, respectively																					8,257,000
research and development, including stock-based compensation of 1,029, 1,698, 5,154 and 5,369, respectively																						38,157,250	40,147,000
selling, general and administrative, including stock-based compensation of 875, 1,864, 5,440 and 5,370, respectively																						10,199,500	11,997,000
impairment loss on intangible asset																											28,638,000
net income before taxes																						-5,495,000	82,603,000			-51,138,000	220,072,000
income tax benefit																											6,014,000							4,009,000			8,652,000																										26,000				102,000
research and development, including stock-based compensation of 1,949, 1,903, 4,125 and 3,671, respectively																								57,301,000
selling, general and administrative, including stock-based compensation of 2,309, 1,863, 4,565 and 3,506, respectively																								14,113,000
research and development, including stock-based compensation of 2,176 and 1,768, respectively																									55,181,000
selling, general and administrative, including stock-based compensation of 2,256 and 1,643, respectively																									14,688,000
research and development, including stock-based compensation of 1,698, 1,472, 5,369 and 4,522, respectively																										12,829,500	26,659,000
selling, general and administrative, including stock-based compensation of 1,864, 1,405, 5,370 and 4,327, respectively																										10,567,750	13,898,000
research and development, including stock-based compensation of 1,903, 1,395, 3,671 and 3,050, respectively																												12,637,000
selling, general and administrative, including stock-based compensation of 1,863, 1,503, 3,506 and 2,922, respectively																												14,263,000
research and development, including stock-based compensation of 1,768 and 1,655, respectively																													12,022,000
selling, general and administrative, including stock-based compensation of 1,643 and 1,419, respectively																													14,110,000
research and development, including stock-based compensation of 1,472, 1,345, 4,522 and 3,698, respectively																														22,035,250	13,769,000
increase in fair value of symphony icon, inc. purchase liability																																					2,101,000		-2,146,000	478,000	965,000	782,000	3,404,000	-12,000	1,753,000	910,000	-1,072,000	448,000	1,142,000	-5,289,000	1,338,000	477,000	1,264,000	-200,000	5,844,000	2,162,000	2,081,000	1,568,000	2,336,000	1,804,000	1,058,000
selling, general and administrative, including stock-based compensation of 1,405, 1,235, 4,327 and 3,516, respectively																														11,797,750	15,579,000
net loss before taxes																														-16,255,000	-27,512,000	-34,706,000	-42,075,000	-27,331,000	-30,722,000	-35,059,000
research and development, including stock-based compensation of 1,395, 1,169, 3,050 and 2,353, respectively																																26,589,000
selling, general and administrative, including stock-based compensation of 1,503, 1,234, 2,922 and 2,281, respectively																																16,755,000
research and development, including stock-based compensation of 1,655 and 1,184, respectively																																	47,783,000
selling, general and administrative, including stock-based compensation of 1,419 and 1,047, respectively																																	14,857,000
subscription and license fees																																		16,000		57,000	7,000	36,000	31,000	88,000		187,000	61,000	38,000			107,000	49,000	105,000	34,000		3,000	76,000		158,000		148,000	23,000	20,000	94,000	80,000	499,000	149,000	69,000		311,500	481,000	202,000	563,000	795,500	310,000	1,613,000	1,259,000	462,500	455,000	171,000	1,224,000	1,120,000	843,000	813,000
research and development, including stock-based compensation of 1,345, 1,051, 3,698 and 3,013, respectively																																		27,413,250	39,137,000
selling, general and administrative, including stock-based compensation of 1,235, 879, 3,516 and 2,709, respectively																																		12,517,250	16,724,000
research and development, including stock-based compensation of 1,169, 973, 2,353 and 1,962, respectively																																				26,934,000
selling, general and administrative, including stock-based compensation of 1,234, 984, 2,281 and 1,830, respectively																																				18,475,000
shares used in computing consolidated net loss per common share, basic and diluted																																				105,300,000	104,461,000	64,000	103,885,000	103,830,000	103,682,000	11,000	103,616,000	103,608,000	724,613,000	19,971,000	514,796,000	514,623,000	513,955,000	137,000	513,419,000	513,083,000	512,428,000	6,014,000	490,049,000	480,634,000	480,324,000	84,406,250	337,678,000	337,668,000	337,527,000
research and development, including stock-based compensation of 1,184 and 989, respectively																																					43,581,000
selling, general and administrative, including stock-based compensation of 1,047 and 846, respectively																																					14,871,000
consolidated net loss before taxes																																					-43,543,000																					-33,845,000	-26,103,000			-22,999,000	-27,539,000			-22,770,000	-22,770,000
research and development, including stock-based compensation of 1,051, 893, 3,013 and 2,865, respectively																																						34,437,750	52,533,000
general and administrative, including...																																						13,967,000	12,263,000	8,416,000	8,398,000	6,448,000	5,379,000	6,307,000	5,701,000	3,988,000	4,617,000	5,152,000	5,654,000	3,412,000	4,716,000	4,669,000	4,324,000	3,920,000	4,396,000	4,162,000	4,565,000	4,010,000	4,055,000	4,532,000	4,753,000	3,861,000	4,948,000	5,068,000	5,519,000	4,425,000	4,568,000	5,551,000	4,762,000	4,457,000	4,692,000	5,603,000	5,529,000	5,345,000	5,091,000	5,004,000	5,300,000	5,058,000	5,309,000	5,664,000
research and development, including stock-based compensation of 973, 868, 1,962 and 1,972, respectively																																								48,216,000
revenues from collaborative agreements																																									12,494,000
research and development, including stock-based compensation of 989 and 1,104, respectively																																									37,002,000
research and development, including stock-based compensation of 893, 797, 2,865 and 3,195, respectively																																										16,186,250	23,111,000
consolidated net incomes																																										86,750,000	-35,282,000	-28,074,000	-28,076,000	-2,933,000	-40,498,000	-26,028,000	-30,835,000	-17,414,000	-31,658,000	-29,080,000	-25,974,000	-24,873,000	-29,539,000	-25,931,000	-29,868,000	-33,845,000	-26,103,000	-26,638,000	-29,629,000	-22,999,000	-27,513,000	-25,193,000	-26,070,000	-22,770,000	-22,668,000	-23,542,000	-24,337,000
consolidated net loss per common share, basic and diluted																																										830	-340	-270	-40		-80	-50	-60	-30	-60	-60	-50	-50	-60	-50	-60	-60	-80	-80	-90
research and development, including stock-based compensation of 868, 940, 1,972 and 2,398, respectively																																												20,769,000
research and development, including stock-based compensation of 1,104 and 1,458, respectively																																													20,865,000
collaborative research																																														277,750	312,000	627,000	172,000	1,376,000	238,000	211,000	284,000	218,000	214,000	199,000	152,000	320,000	335,000	461,000	516,000	754,000	632,000	1,164,000	1,641,000	2,010,500	1,650,000	2,787,000	3,605,000	5,697,250	7,202,000	7,953,000	7,634,000	8,615,000	9,712,000	12,477,000	12,271,000	14,946,000	18,770,000	15,351,000
research and development, including stock-based compensation of 797, 1,027, 3,195 and 3,379, respectively																																														17,312,000	24,108,000
interest income																																														4,250	5,000	4,000	8,000	21,000	39,000	44,000	53,000	55,000	44,000	58,000	56,000	40,000	60,000	68,000	87,000	51,000	51,000	200,000	217,000	167,250	103,000	239,000	327,000	1,288,750	956,000	1,418,000	2,781,000	952,750	2,166,000	765,000	880,000	976,000	774,000	900,000
other income																																														225,500	282,000	534,000	86,000	18,000	11,000	-4,000	34,000	84,000	4,000	21,000	-4,000	8,000	88,000	30,000	27,000															-14,000	-12,000	470,000	-6,000	-56,000
research and development, including stock-based compensation of 940, 1,022, 2,398 and 2,352, respectively																																																21,187,000
research and development, including stock-based compensation of 1,458 and 1,330, respectively																																																	23,953,000
research and development, including stock-based compensation of 1,027, 923, 3,379 and 2,875, respectively																																																		17,354,750	25,400,000
research and development, including stock-based compensation of 1,022, 915, 2,352 and 1,952, respectively																																																				23,692,000
research and development, including stock-based compensation of 1,330 and 1,037, respectively																																																					20,327,000
research and development, including stock-based compensation of 923, 823, 2,875 and 2,480, respectively																																																						15,396,000	19,192,000
research and development, including stock-based compensation of 915, 818, 1,952 and 1,657, respectively																																																								19,355,000
research and development, including stock-based compensation of 1,037 and 839, respectively																																																									23,037,000
research and development, including stock-based compensation of 823, 751, 2,480 and 2,366, respectively																																																										15,930,250	19,655,000
gain on investments																																																																53,000	88,000
research and development, including stock-based compensation of 818, 809, 1,657 and 1,615, respectively																																																												20,145,000
research and development, including stock-based compensation of 839 and 806, respectively																																																													23,921,000
research and development, including stock-based compensation of 751, 733, 2,366 and 2,328, respectively																																																														15,353,250	20,086,000
other expense																																																														1,000	-2,700,000	-643,000	-682,000	-509,250	-516,000	-576,000	-945,000	-405,250	-535,000	-539,000	-547,000	-8,500	-8,000
less: net loss attributable to noncontrolling interest in symphony icon, inc.																																																																		765,000	3,526,000	3,469,000	2,777,000
net loss attributable to lexicon pharmaceuticals, inc.																																																														-22,999,000	-27,513,000	-25,193,000	-26,070,000	-22,005,000	-19,142,000	-20,073,000	-21,560,000
net loss attributable to lexicon pharmaceuticals, inc. per common share, basic and diluted																																																														-70	-80	-70	-130	-130	-140	-150	-160
shares used in computing net loss attributable to lexicon pharmaceuticals, inc. per common share, basic and diluted																																																														11,648,000	337,404,000	337,404,000	197,239,000	8,225,000	137,313,000	137,331,000	137,075,000
research and development, including stock-based compensation of 809, 766, 1,615 and 1,595, respectively																																																																20,239,000
research and development, including stock-based compensation of 806 and 829, respectively																																																																	21,088,000
research and development, including stock-based compensation of 733, 836, 2,328, and 2,913, respectively																																																																		15,601,000	19,320,000
gain (loss) on investments																																																																		252,000	185,000
research and development, including stock-based compensation of 766, 950, 1,595, and 2,077, respectively																																																																				20,220,000
gain on long-term investments																																																																				306,000	517,000
research and development, including stock-based compensation of 829 and 1,127, respectively																																																																					22,976,000
research and development, including stock-based compensation of 836, 965, 2,913 and 3,000, respectively																																																																						21,448,250	27,642,000
impairment of long-term investments																																																																						-830,500	-3,322,000
loss before noncontrolling interest in symphony icon, inc.																																																																						-19,430,000	-28,398,000	-26,182,000	-22,874,000	-16,446,000	-17,978,000	-17,894,000
loss attributable to noncontrolling interest in symphony icon, inc.																																																																						4,013,000	4,939,000	6,148,000	4,924,000	4,269,000	3,867,000	4,303,000
research and development, including stock-based compensation of 950, 1,044, 2,077 and 2,035, respectively																																																																								30,349,000
research and development, including stock-based compensation of 1,127 and 991, respectively																																																																									27,802,000
research and development, including stock-based compensation of 965, 1,101, 3,000 and 3,355, respectively																																																																										19,350,500	24,518,000
research and development, including stock-based compensation of 1,044, 1,105, 2,035 and 2,254, respectively																																																																												25,594,000
research and development, including stock-based compensation of 991 and 1,149, respectively																																																																													27,290,000
research and development, including stock-based compensation of 1,101, 0, 3,355 and (20), respectively																																																																														20,278,750	27,010,000
research and development, including stock-based compensation of 1,105, , 2,254 and (20), respectively																																																																																27,433,000

Balance Sheets:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-07-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30

assets
current assets:
cash and cash equivalents	38,089,000	34,326,000	49,656,000	21,364,000	62,888,000	66,656,000	34,551,000	35,617,000	96,494,000	22,465,000	21,116,000	102,271,000	26,001,000	46,345,000	18,834,000	21,450,000	59,520,000	64,065,000	92,118,000	89,887,000	97,652,000	126,263,000	52,251,000	86,943,000	55,592,000	36,112,000	170,203,000	11,106,000	45,778,000	48,902,000	15,044,000	20,421,000	61,661,000	83,293,000	30,706,000	2,455,000	46,600,000	38,772,000	38,410,000	24,681,000	202,989,000	61,674,000	9,744,000	41,960,000	137,266,000	26,775,000	27,725,000	46,517,000	37,499,000	19,581,000	23,254,000	34,248,000	30,423,000	20,759,000	33,779,000	29,010,000	186,309,000	30,521,000	20,328,000	20,118,000	47,208,000	211,988,000	247,698,000	260,126,000	100,554,000	62,736,000	49,166,000	16,953,000	85,873,000	100,209,000	109,649,000	109,649,000	59,457,000	22,938,000	50,721,000	22,587,000	19,608,000	30,226,000	12,118,000	14,542,000
short-term investments	132,569,000	61,904,000	66,294,000	117,643,000	131,951,000	171,301,000	223,818,000	274,347,000	259,104,000	147,561,000	197,311,000	154,468,000	79,936,000	92,012,000	117,369,000	40,518,000	26,982,000	22,678,000	28,800,000	28,614,000	43,709,000	26,012,000	59,195,000	114,923,000	193,545,000	235,547,000	126,101,000	94,871,000	87,367,000	138,395,000	194,645,000	241,851,000	249,127,000	113,524,000	200,481,000	257,288,000	299,904,000	356,784,000	390,955,000	452,465,000
accounts receivable	11,779,000	2,384,000	2,334,000	2,183,000	47,447,000	3,473,000	2,895,000	2,620,000	1,526,000	1,010,000	318,000	685,000	261,000	28,000	39,000	34,000	37,000	14,000	23,000	159,000	101,000	395,000	1,383,000	30,876,000	30,135,000	56,532,000	56,841,000	5,580,000	4,390,000	2,913,000	4,406,000	4,482,000	4,825,000	10,597,000	5,014,000	8,733,000	7,492,000	738,000	1,018,000	741,000	911,000	72,000	316,000	170,000	1,035,000	165,000	281,000	471,000	790,000	895,000	1,014,000	863,000	1,378,000	233,000	182,000	186,000	350,000	489,000	505,000	831,000	744,000	1,340,000	2,083,000	1,969,000	815,000	1,347,000	530,000	1,248,000	568,000	770,000	672,000	672,000	1,244,000	1,763,000	1,747,000	1,357,000	1,722,000	1,186,000	2,064,000	4,896,000
inventory	276,000	281,000	158,000	168,000	201,000	231,000	636,000	585,000	514,000	381,000	336,000	172,000												3,989,000	4,147,000	4,243,000	4,476,000	4,277,000	4,606,000	4,755,000	2,142,000	2,112,000	1,948,000	2,149,000	811,000	236,000
prepaid expenses and other current assets	3,319,000	3,000,000	4,085,000	3,726,000	3,319,000	4,532,000	6,706,000	7,675,000	7,009,000	5,130,000	4,291,000	6,124,000	3,348,000	2,481,000	2,821,000	2,896,000	1,892,000	2,164,000	3,064,000	4,598,000	3,954,000	5,049,000	9,109,000	9,461,000	8,195,000	5,320,000	5,973,000	6,625,000	4,686,000	3,395,000	3,954,000	4,284,000	4,434,000	4,458,000	10,174,000	10,376,000	3,878,000	2,443,000	9,071,000	14,271,000	10,137,000	10,953,000	7,151,000	3,194,000	4,764,000	5,937,000	7,342,000	6,570,000	4,636,000	7,257,000	6,684,000	8,438,000	6,349,000	9,004,000	6,582,000	5,143,000	3,748,000	4,337,000	3,874,000	3,448,000	2,883,000	3,259,000	8,589,000	5,757,000	6,356,000	7,217,000	8,017,000	3,703,000	5,487,000	7,069,000	8,321,000	8,321,000	3,623,000	4,112,000	3,740,000	3,692,000	3,537,000	4,367,000	3,350,000	3,639,000
total current assets	186,032,000	101,895,000	122,527,000	145,084,000	245,806,000	246,193,000	268,606,000	320,844,000	364,647,000	176,547,000	223,372,000	263,720,000	109,546,000	140,866,000	139,063,000	64,898,000	88,431,000	88,921,000	124,005,000	123,258,000	145,416,000	157,719,000	121,938,000	246,192,000	291,614,000	337,754,000	363,594,000	122,459,000	146,827,000	198,360,000	220,191,000	273,150,000	321,995,000	214,021,000	247,186,000	279,088,000	357,874,000	398,737,000	439,454,000	492,158,000	532,400,000	288,947,000	313,799,000	342,310,000	368,987,000	87,820,000	86,667,000	105,408,000	134,554,000	159,362,000	183,076,000	206,464,000	230,935,000	216,085,000	238,277,000	258,985,000	285,790,000	148,981,000	169,193,000	193,189,000	214,738,000	235,617,000	282,453,000	321,907,000	169,684,000	133,710,000	95,952,000	94,215,000	109,167,000	131,425,000	152,950,000	152,950,000	174,375,000	264,650,000	279,402,000	100,281,000	64,777,000	85,552,000	58,437,000	73,862,000
property and equipment	1,753,000	1,863,000	1,981,000	2,132,000	2,308,000	2,484,000	2,135,000	1,954,000	1,843,000	1,987,000	2,134,000	2,202,000	2,207,000	2,071,000	932,000	1,035,000	1,142,000	1,176,000	1,311,000	1,201,000	296,000	295,000	11,106,000	11,524,000	13,582,000	14,047,000	14,540,000	15,007,000	15,475,000	16,299,000	16,772,000	17,244,000	17,687,000	18,167,000	18,588,000	18,995,000	19,390,000	19,854,000	20,350,000	20,753,000	21,227,000	795,000	684,000	732,000	1,080,000	1,494,000	39,177,000	39,959,000	41,362,000	41,838,000	42,152,000	42,623,000	42,634,000	43,515,000	44,526,000	45,526,000	46,417,000	47,344,000	48,370,000	51,815,000	53,427,000	55,404,000	56,552,000	57,850,000	58,754,000	60,090,000	61,526,000	63,027,000	65,087,000	66,444,000	68,104,000	68,104,000	69,650,000	70,829,000	72,350,000	74,214,000	76,041,000	78,192,000	80,351,000	82,174,000
goodwill	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	44,543,000	25,798,000	25,798,000	25,798,000	25,798,000	25,798,000	25,798,000	25,798,000	25,798,000	25,798,000	25,798,000	25,798,000	25,798,000	25,798,000	25,798,000	25,798,000	25,798,000	25,798,000	25,798,000	25,798,000
operating lease right-of-use-assets	7,123,000	7,318,000	7,508,000	4,456,000	4,646,000	4,832,000	5,011,000	5,187,000	5,358,000	5,524,000	5,687,000	6,259,000	6,420,000	6,819,000
restricted cash	29,000,000	29,000,000	29,000,000	29,000,000
other assets	368,000	368,000	368,000	368,000	368,000	368,000	828,000	828,000	828,000	828,000	743,000				7,147,000	1,849,000	2,062,000	2,269,000	2,471,000	2,670,000	3,005,000	1,231,000	1,341,000	1,448,000	1,553,000	1,655,000	1,754,000	1,898,000	1,993,000	429,000	429,000	432,000	429,000	429,000	428,000	428,000	461,000	454,000	430,000	530,000	3,305,000	3,498,000	3,581,000	3,740,000	3,409,000	108,000	120,000	133,000	144,000	158,000	65,000	88,000	109,000	135,000	157,000	181,000	205,000	281,000	253,000	304,000	619,000	497,000	352,000	3,656,000	3,525,000	4,086,000	4,648,000	5,209,000	5,770,000	6,358,000	6,894,000	6,894,000	7,462,000	8,019,000	642,000	669,000	752,000	724,000	762,000	797,000
total assets	268,819,000	184,987,000	205,927,000	225,583,000	297,671,000	298,420,000	321,123,000	373,356,000	417,219,000	229,429,000	276,479,000	316,724,000	162,716,000	194,299,000	191,685,000	112,325,000	136,178,000	136,909,000	172,330,000	171,672,000	193,260,000	203,788,000	178,928,000	322,540,000	370,567,000	417,715,000	444,588,000	233,143,000	258,516,000	310,192,000	332,937,000	386,813,000	436,539,000	329,487,000	363,513,000	396,264,000	475,625,000	516,945,000	558,134,000	611,341,000	654,832,000	391,140,000	415,964,000	444,682,000	471,376,000	187,522,000	224,064,000	243,600,000	274,160,000	299,458,000	323,393,000	347,275,000	371,778,000	357,835,000	381,060,000	402,792,000	430,512,000	294,706,000	315,916,000	343,408,000	366,884,000	370,873,000	365,155,000	409,211,000	257,761,000	223,684,000	244,333,000	244,452,000	261,508,000	283,703,000	310,306,000	310,306,000	336,573,000	369,296,000	378,192,000	200,962,000	167,368,000	190,266,000	165,348,000	182,671,000
liabilities and stockholders’ equity
current liabilities:
accounts payable	2,996,000	3,083,000	3,797,000	5,899,000	10,689,000	14,801,000	14,201,000	12,220,000	8,067,000	14,389,000	12,036,000	10,501,000	10,311,000	10,395,000	9,427,000	7,347,000	9,321,000	9,152,000	8,345,000	8,545,000	4,926,000	5,469,000	11,734,000	29,763,000	18,236,000	12,178,000	20,907,000	10,028,000	13,874,000	51,480,000	50,451,000	66,553,000	57,652,000	52,628,000	43,857,000	41,945,000	52,877,000	41,545,000	28,225,000	25,544,000	19,725,000	16,355,000	11,291,000	12,142,000	13,064,000	9,741,000	8,350,000	7,072,000	9,715,000	9,709,000	6,281,000	5,442,000	7,661,000	4,306,000	4,579,000	5,324,000	6,042,000	5,526,000	3,671,000	5,452,000	3,159,000	3,550,000	3,547,000	4,773,000	5,919,000	3,413,000	3,210,000	3,083,000	7,926,000	8,055,000	7,920,000	7,920,000	4,252,000	7,344,000	4,913,000	4,701,000	4,366,000	6,513,000	4,269,000	4,326,000
accrued liabilities	6,902,000	13,189,000	13,620,000	11,481,000	12,948,000	30,447,000	21,845,000	15,656,000	15,332,000	17,157,000	20,225,000	15,608,000	10,060,000	12,777,000	9,018,000	9,515,000	9,584,000	12,972,000	14,208,000	12,595,000	22,409,000	29,691,000	58,497,000	57,338,000	51,349,000	42,151,000	11,511,000	9,083,000	10,800,000	13,794,000	12,865,000	12,863,000	12,282,000	12,729,000	10,959,000	10,191,000	32,114,000	32,906,000	23,950,000	23,615,000	24,757,000	14,913,000	10,807,000	11,769,000	10,120,000	13,134,000	10,886,000	7,952,000	7,674,000	11,529,000	11,321,000	9,704,000	8,922,000	12,782,000	15,045,000	13,710,000	13,786,000	7,703,000	8,037,000	7,688,000	6,264,000	7,437,000	6,285,000	5,368,000	5,611,000	6,812,000	6,863,000	5,106,000	6,615,000	9,338,000	8,489,000	8,489,000	9,393,000	9,093,000	8,593,000	7,556,000	6,772,000	7,325,000	9,525,000	8,054,000
current portion of long-term debt		4,595,000			42,056,000																																16,280,000				2,015,000	18,788,000	19,255,000	19,711,000	20,167,000	20,609,000	1,783,000	1,746,000	1,710,000	1,675,000	22,678,000	1,607,000	1,574,000	1,542,000	1,510,000	1,478,000	1,443,000	1,413,000	1,380,000	1,155,000	1,138,000	1,114,000	17,100,000	36,599,000	38,482,000	38,860,000	1,004,000	984,000	963,000	944,000	924,000	924,000	905,000	880,000	861,000	844,000	826,000	816,000	4,800,000	4,783,000
total current liabilities	9,898,000	20,867,000	21,720,000	34,836,000	110,693,000	45,248,000	36,046,000	27,876,000	23,399,000	31,546,000	32,261,000	26,109,000	20,371,000	23,172,000	18,445,000	16,862,000	18,905,000	22,124,000	34,246,000	32,815,000	38,995,000	46,806,000	78,922,000	97,558,000	80,319,000	65,341,000	44,824,000	22,469,000	28,221,000	68,506,000	81,336,000	100,370,000	124,127,000	128,728,000	133,173,000	137,061,000	164,643,000	170,113,000	130,992,000	121,943,000	122,996,000	51,799,000	43,571,000	45,933,000	44,969,000	44,269,000	21,896,000	17,673,000	19,294,000	23,598,000	40,903,000	17,381,000	18,285,000	19,051,000	21,555,000	20,933,000	21,390,000	14,806,000	13,226,000	14,480,000	10,775,000	12,948,000	27,446,000	47,316,000	50,954,000	50,166,000	12,351,000	12,282,000	21,176,000	25,007,000	27,656,000	27,656,000	27,691,000	35,347,000	37,345,000	39,495,000	43,162,000	45,966,000	48,216,000	54,491,000
long-term debt	49,684,000	49,408,000	56,508,000	56,107,000	58,643,000	100,298,000	99,895,000	99,499,000	99,874,000	99,508,000	99,265,000	98,772,000	48,845,000	48,579,000	23,784,000	23,631,000	23,477,000						11,629,000	234,807,000	234,488,000	234,171,000	233,837,000	243,953,000	243,912,000	243,830,000	232,198,000	231,879,000	231,576,000	85,512,000	85,383,000	85,268,000	85,167,000	85,038,000	84,909,000	100,550,000	103,793,000	87,500,000	87,500,000	87,500,000	87,500,000		19,255,000	19,711,000	20,167,000	20,609,000		21,457,000	21,877,000	22,284,000	22,678,000	23,063,000	23,451,000	23,826,000	24,188,000	27,044,000	27,345,000	27,640,000	27,922,000	28,199,000	28,482,000	28,754,000	65,970,000	43,939,000	29,529,000	29,779,000	30,018,000	30,018,000	30,251,000	30,493,000	30,723,000	30,942,000	31,156,000	31,372,000	31,584,000	31,785,000
other long-term liabilities	6,381,000	7,174,000	7,540,000	5,200,000	5,303,000	6,924,000	6,670,000	6,001,000							5,438,000	1,002,000	1,098,000	1,190,000	1,481,000	1,624,000	1,718,000	611,000	738,000	862,000	983,000	1,102,000	1,215,000	1,325,000	1,433,000	252,000	265,000	279,000	292,000	303,000	313,000	559,000	805,000	2,500,000	14,037,000	14,593,000	14,367,000	23,520,000	23,036,000	23,259,000	23,535,000	34,005,000	34,821,000	34,017,000	32,386,000	37,391,000	35,256,000	34,079,000	32,283,000	31,086,000	59,276,000	57,170,000	55,146,000	53,636,000	51,357,000	49,610,000	48,783,000	47,219,000	540,000	579,000	616,000	653,000	690,000	727,000	764,000	764,000	764,000	764,000	764,000	759,000	754,000	749,000	744,000	739,000	735,000	730,000
total liabilities	65,963,000	77,449,000	85,768,000	96,143,000	174,639,000	152,470,000	142,611,000	133,376,000	128,352,000	136,319,000	136,969,000	130,363,000	74,670,000	77,175,000	47,667,000	41,495,000	43,480,000	23,314,000	35,727,000	34,439,000	40,713,000	47,417,000	91,289,000	333,227,000	315,790,000	300,614,000	279,876,000	298,029,000	304,203,000	339,593,000	338,008,000	360,619,000	384,437,000	251,111,000	257,200,000	261,661,000	318,224,000	331,764,000	340,801,000	358,460,000	368,982,000	193,202,000	184,490,000	187,075,000	187,358,000	109,698,000	107,396,000	102,825,000	103,997,000	113,748,000	108,309,000	105,067,000	105,100,000	105,076,000	136,164,000	133,821,000	132,944,000	125,225,000	121,728,000	124,091,000	119,860,000	102,019,000	70,120,000	90,306,000	94,264,000	93,785,000	93,223,000	71,160,000	65,681,000	69,762,000	72,650,000	72,650,000	73,425,000	82,725,000	86,823,000	91,119,000	98,364,000	104,765,000	110,698,000	120,816,000
commitments and contingencies
stockholders’ equity:
convertible preferred stock, 0.01 par value...	4,000
common stock, 0.001 par value...	426,000	366,000	366,000	366,000	366,000	363,000	363,000	363,000	248,000	245,000	245,000	245,000	190,000	189,000	189,000	150,000	150,000	150,000	150,000	146,000	145,000	142,000	117,000	108,000	108,000
additional paid-in capital	2,224,025,000	2,129,912,000	2,127,005,000	2,123,560,000	2,120,365,000	2,117,325,000	2,115,891,000	2,113,090,000	2,108,497,000	1,862,558,000	1,859,346,000	1,855,659,000	1,712,558,000	1,709,144,000	1,705,607,000	1,608,730,000	1,605,898,000	1,608,749,000	1,606,142,000	1,583,653,000	1,580,891,000	1,561,096,000	1,486,853,000	1,470,862,000	1,466,604,000	1,462,172,000	1,458,693,000	1,455,131,000	1,451,365,000	1,444,925,000	1,441,890,000	1,438,625,000	1,435,526,000	1,433,263,000	1,430,630,000	1,423,911,000	1,411,222,000	1,406,311,000	1,402,190,000	1,399,665,000	1,397,646,000	1,396,207,000	1,394,421,000	1,391,932,000	1,389,997,000	1,181,015,000	1,179,358,000	1,177,432,000	1,175,108,000	1,173,205,000	1,170,928,000	1,168,961,000	1,166,605,000	1,127,832,000	1,090,485,000	1,088,666,000	1,087,033,000	925,230,000	923,797,000	922,319,000	920,324,000	919,161,000	917,828,000	916,505,000	733,874,000	677,546,000	676,001,000	674,645,000	672,838,000	671,484,000	670,064,000	670,064,000	668,481,000	666,702,000	663,772,000	464,105,000	439,589,000	437,180,000	392,506,000	386,995,000
accumulated deficit	-2,018,626,000	-2,017,583,000	-2,002,054,000	-1,989,285,000	-1,992,537,000	-1,967,242,000	-1,933,476,000	-1,868,665,000	-1,815,236,000	-1,766,839,000	-1,717,083,000	-1,666,558,000	-1,621,654,000	-1,589,720,000	-1,559,226,000	-1,535,839,000	-1,511,252,000	-1,487,776,000	-1,462,165,000	-1,439,043,000	-1,420,976,000	-1,400,018,000	-1,394,523,000	-1,477,126,000	-1,408,055,000	-1,341,444,000	-1,290,306,000	-1,516,392,000	-1,493,374,000	-1,471,485,000	-1,443,973,000	-1,409,267,000	-1,381,404,000	-1,353,026,000	-1,322,304,000	-1,287,245,000	-1,250,363,000	-1,217,944,000	-1,181,929,000	-1,143,817,000	-1,108,934,000	-1,195,684,000	-1,160,402,000	-1,132,328,000	-1,104,252,000	-1,101,319,000	-1,060,821,000	-1,034,793,000	-1,003,958,000	-986,544,000	-954,886,000	-925,806,000	-899,832,000	-874,959,000	-845,420,000	-819,489,000	-789,621,000	-755,776,000	-729,673,000	-703,035,000	-673,406,000	-650,407,000	-622,894,000	-597,701,000	-570,175,000	-548,170,000	-529,028,000	-508,955,000	-487,395,000	-471,978,000	-448,519,000	-448,519,000	-428,485,000	-410,535,000	-398,358,000	-384,247,000	-370,656,000	-351,741,000	-337,918,000	-325,163,000
accumulated other comprehensive income	-130,000	30,000	29,000	-14,000	25,000	119,000	349,000	-193,000	-50,000	31,000								-10,000			5,000	-6,000	35,000	312,000	860,000		36,000	86,000	33,000
treasury stock	-2,843,000	-5,187,000	-5,187,000	-5,187,000	-5,187,000	-4,615,000	-4,615,000	-4,615,000	-4,615,000	-2,885,000	-2,885,000	-2,885,000	-2,885,000	-2,061,000	-2,061,000	-2,061,000	-2,061,000	-7,518,000	-7,518,000	-7,518,000	-7,518,000	-4,843,000	-4,843,000	-4,843,000	-4,740,000	-3,817,000	-3,817,000	-3,817,000	-3,817,000	-2,876,000	-2,876,000	-2,876,000	-1,904,000	-1,904,000	-1,904,000	-1,904,000	-3,368,000	-3,368,000	-3,368,000	-3,368,000	-2,747,000	-2,747,000	-2,747,000	-2,747,000	-2,390,000	-2,390,000	-2,390,000	-2,390,000	-1,503,000	-1,503,000	-1,503,000	-1,503,000	-630,000	-630,000	-630,000	-630,000	-345,000	-345,000	-345,000	-345,000	-237,000	-237,000	-237,000	-237,000	-88,000	-88,000
total stockholders’ equity	202,856,000		120,159,000	129,440,000	123,032,000		178,512,000	239,980,000	288,867,000		139,510,000	186,361,000	88,046,000		144,018,000	70,830,000	92,698,000		136,603,000	137,233,000	152,547,000		87,639,000		54,777,000		164,712,000																																										185,580,000	199,681,000	218,457,000	218,457,000	237,801,000	256,300,000	265,389,000	79,935,000	69,004,000	85,501,000	54,650,000	61,855,000
total liabilities and stockholders’ equity	268,819,000	184,987,000	205,927,000	225,583,000	297,671,000	298,420,000	321,123,000	373,356,000	417,219,000	229,429,000	276,479,000	316,724,000	162,716,000	194,299,000	191,685,000	112,325,000	136,178,000		172,330,000																																																		261,508,000	283,703,000	310,306,000	310,306,000	336,573,000	369,296,000	378,192,000	200,962,000	167,368,000	190,266,000	165,348,000	182,671,000
stockholders' equity:
preferred stock, 0.01 par value...
total stockholders' equity		107,538,000				145,950,000				93,110,000				117,124,000				113,595,000				156,371,000				117,101,000
deferred revenue			4,303,000	17,456,000	45,000,000
series a convertible preferred stock; 2,304,147 shares issued and none outstanding at march 31, 2025 and december 31, 2024
series a convertible preferred stock; 2,304,147 shares issued and none outstanding at december 31, 2024; no shares issued or outstanding at december 31, 2023
series a convertible preferred stock; 2,304,147 shares issued and none outstanding at september 30, 2024; no shares issued or outstanding at december 31, 2023
series a convertible preferred stock; 2,304,147 shares issued and none outstanding at june 30, 2024; no shares issued or outstanding at december 31, 2023
long-term operating lease liabilities									5,079,000	5,265,000	5,443,000	5,482,000	5,454,000	5,424,000
series a convertible preferred stock, 2,304,147 and no shares issued, respectively									23,000
accumulated other comprehensive loss											-113,000	-100,000	-163,000	-428,000	-491,000	-150,000	-37,000		-6,000	-5,000										-71,000	-218,000	-394,000	-222,000	-63,000	-214,000	-264,000	-195,000				-219,000																					-1,000				-1,000	-1,000	-5,000			-3,225,000	-3,225,000	-2,332,000	-4,000	-162,000	-9,000	-7,000	-16,000	-4,000	-42,000
liabilities and equity
current portion of long-term debt, net of deferred issuance costs																			11,693,000	11,675,000	11,660,000		8,691,000	10,457,000	10,734,000		11,289,000	1,115,000	1,115,000	1,115,000	12,896,000	13,517,000		14,633,000	15,156,000	15,753,000		16,792,000	17,289,000	2,020,000
total liabilities and equity																		136,909,000		171,672,000	193,260,000	203,788,000	178,928,000		370,567,000	417,715,000	444,588,000	233,143,000	258,516,000	310,192,000	332,937,000	386,813,000	436,539,000	329,487,000	363,513,000	396,264,000	475,625,000	516,945,000	558,134,000	611,341,000	654,832,000	391,140,000	415,964,000	444,682,000	471,376,000	187,522,000	224,064,000	243,600,000	274,160,000	299,458,000	323,393,000	347,275,000	371,778,000	357,835,000	381,060,000	402,792,000	430,512,000	294,706,000	315,916,000	343,408,000	366,884,000	370,873,000	365,155,000	409,211,000	257,761,000	223,684,000	244,333,000	244,452,000
intangible assets																										19,716,000
current portion of long-term debt, net of deferred financing costs																						11,646,000				11,012,000							14,094,000
intangible assets, net of accumulated amortization of 5,886 and 5,003, respectively																								18,833,000
stockholders’ equity/
total stockholders’ equity/																								-10,687,000
total liabilities and equity/																								322,540,000
intangible assets, net of accumulated amortization of 5,444 and 5,003, respectively																									19,275,000
current portion of deferred revenue																											1,117,000	2,243,000	2,432,000	2,117,000	5,124,000	7,437,000	40,099,000	48,738,000	63,201,000	69,172,000	63,372,000	78,870,000	61,528,000	70,764,000	76,499,000	1,743,000	2,218,000	2,311,000	1,618,000	785,000	877,000	903,000	195,000	685,000	623,000	628,000	128,000	421,000	421,000	421,000	119,000	164,000	138,000	185,000	214,000	847,000	514,000	576,000	942,000	1,081,000	1,274,000	3,109,000	5,672,000	6,670,000	10,323,000	10,323,000	13,141,000	18,030,000	22,978,000	26,394,000	31,198,000	31,312,000	29,622,000	37,328,000
deferred revenue, net of current portion																												24,268,000	24,623,000	20,991,000	18,195,000	22,077,000	22,428,000	26,545,000	28,308,000	28,750,000	48,934,000	55,438,000	92,188,000	102,699,000	109,151,000	11,708,000	11,708,000	11,708,000	12,679,000	12,679,000	12,679,000	12,679,000	13,405,000	13,405,000	13,405,000	13,405,000	13,910,000	13,910,000	13,910,000	13,910,000	14,212,000	14,212,000	14,212,000	14,212,000	14,212,000	14,212,000	14,212,000	14,212,000	14,212,000	14,212,000	14,212,000	14,212,000	14,212,000	14,212,000	14,212,000	14,212,000	14,719,000	16,126,000	18,001,000	19,933,000	23,302,000	26,688,000	30,163,000	33,810,000
deferred tax liabilities																												6,014,000	6,014,000	6,014,000	6,014,000	6,014,000	6,014,000	10,023,000	10,023,000	10,023,000	18,675,000	18,675,000	18,675,000	18,675,000	18,675,000	18,675,000	18,675,000	18,675,000	18,675,000	18,745,000	18,745,000	18,745,000	18,745,000	18,745,000	18,745,000	18,745,000	18,745,000	18,745,000	18,745,000	18,745,000	18,745,000	18,745,000	18,745,000	18,745,000	18,745,000
stockholders' equity
preferred stock, .01 par value...
common stock, .001 par value...																										106,000	106,000	106,000	106,000	106,000	106,000	106,000	106,000	106,000	105,000	105,000	105,000	104,000	104,000	104,000	104,000	104,000	104,000	727,000	726,000	516,000	516,000	516,000	514,000	514,000	514,000	514,000	512,000	495,000	481,000	481,000	480,000	338,000	338,000	338,000	338,000	338,000	338,000	338,000	176,000	137,000	137,000	137,000	137,000	137,000	137,000	137,000	137,000	137,000	137,000	86,000	78,000	78,000	66,000	65,000
accumulated other comprehensive gain																										84,000												78,000	336,000	297,000		58,000	98,000	23,000	-63,000	2,000	5,000	10,000	2,000	38,000	31,000	42,000	23,000	21,000	-20,000	-57,000	21,000	34,000	71,000	40,000	5,000									38,000
other intangible assets, net of accumulated amortization of 4,561 and 3,237, respectively																											20,157,000
stockholders’ equity
other intangible assets, net of accumulated amortization of 4,120 and 3,237, respectively																												49,236,000
equity
total deficit																												-64,886,000	-45,687,000
revenues:
net product revenue																												8,672,000	6,740,000
collaborative agreements																												860,000	2,439,000
royalties and other revenue																												150,000	37,000
total revenues																												9,682,000	9,216,000
operating expenses:
cost of sales																												1,327,000	553,000
research and development, including stock-based compensation of 1,903, 1,395, 3,671 and 3,050, respectively																												12,637,000
selling, general and administrative, including stock-based compensation of 1,863, 1,503, 3,506 and 2,922, respectively																												14,263,000
total operating expenses																												28,227,000	26,685,000
income from operations																												-18,545,000	-17,469,000
interest expense																												-5,164,000	-5,117,000
interest and other income																												691,000	789,000
net income																												-23,018,000	-21,797,000
net income per common share, basic and diluted																												-220	-210
shares used in computing net income per common share, basic and diluted																												106,272,000	106,054,000
other comprehensive income:
unrealized gain on investments																												53,000	45,000
comprehensive loss																												-22,965,000	-21,752,000
other intangible assets, net of accumulated amortization of 3,678 and 3,237, respectively																													49,678,000
research and development, including stock-based compensation of 1,768 and 1,655, respectively																													12,022,000
selling, general and administrative, including stock-based compensation of 1,643 and 1,419, respectively																													14,110,000
other intangible assets, net of accumulated amortization of 2,795 and 1,471, respectively																														50,561,000
equity:
total equity																														-29,401,000	-5,071,000	26,194,000	52,102,000	78,376,000	106,313,000	134,603,000	157,401,000	185,181,000	217,333,000	252,881,000	285,850,000	197,938,000	231,474,000	257,607,000	284,018,000	77,824,000	116,668,000	140,775,000	170,163,000	185,710,000	215,084,000	242,208,000	266,678,000	252,759,000	244,896,000	268,971,000	297,568,000	169,481,000	194,188,000	219,317,000	247,024,000	268,854,000	295,035,000	318,905,000	163,497,000	129,899,000	151,110,000	173,292,000
other intangible assets, net of accumulated amortization of 2,354 and 1,471, respectively																															51,002,000
other intangible assets, net of accumulated amortization of 1,912 and 1,471, respectively																																51,444,000
other intangible assets																																	51,885,000				53,357,000	53,357,000	53,357,000	53,357,000	53,357,000	53,357,000	53,357,000	53,357,000	53,357,000	53,557,000	53,557,000	53,557,000	53,557,000	53,557,000	53,557,000	53,557,000	53,557,000	53,557,000	53,557,000	53,557,000	53,557,000	53,557,000	53,557,000	53,557,000	53,557,000	53,557,000
other intangible assets, net of accumulated amortization of 1,030 and 0, respectively																																		52,327,000
other intangible assets, net of accumulated amortization of 589 and 0, respectively																																			52,768,000
other intangible assets, net of accumulated amortization of 147 and 0, respectively																																				53,210,000
short-term investments, including restricted investments of 0 and 430, respectively																																									318,363,000
assets held for sale																																										21,500,000	23,849,000	23,849,000	23,849,000	23,849,000
short-term investments, including restricted investments of 430																																										194,748,000	272,739,000	273,137,000	202,073,000	31,094,000	51,319,000	51,850,000	91,629,000	131,629,000	152,124,000	162,915,000	192,785,000	186,089,000	197,734,000	224,646,000	95,383,000	113,634,000	144,486,000	168,792,000	163,903,000	19,030,000	24,083,000	54,055,000	56,542,000	56,727,000	30,504,000	60,479,000	629,000	2,230,000	7,426,000	7,426,000	76,630,000	199,171,000	183,624,000	27,654,000	39,910,000	49,773,000	40,905,000	50,785,000
short-term investments held by symphony icon, inc.																																																																	5,417,000	5,683,000	7,735,000	11,832,000	16,610,000	21,147,000	26,882,000	26,882,000	33,421,000	36,666,000	39,570,000	44,991,000
lexicon pharmaceuticals, inc. stockholders’ equity:
total lexicon pharmaceuticals, inc. stockholders’ equity																																																													247,024,000	268,854,000	295,035,000	318,905,000	163,787,000	129,424,000	147,109,000	165,822,000
noncontrolling interest in symphony icon, inc.																																																																	-290,000	475,000	4,001,000	7,470,000	10,247,000	14,260,000	19,199,000	19,199,000	25,347,000	30,271,000	25,980,000	29,908,000
long-term investments																																																																			56,409,000	56,203,000	55,686,000	53,678,000	56,560,000	56,560,000	59,288,000
liabilities, noncontrolling interest and stockholders’ equity
intangible assets, net of amortization of 6,000 and 5,360, respectively
deferred stock compensation
other receivables
intangible assets, net of amortization of 5,960 and 5,360, respectively																																																																																40,000

Cashflow Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30

cash flows from operating activities:
net loss	-1,043,000	-15,530,000	-12,768,000			-33,766,000	-64,811,000	-53,429,000	-48,397,000	-49,756,000	-50,525,000	-44,904,000	-31,934,000	-30,494,000	-23,387,000	-24,587,000	-23,476,000		-23,122,000	-18,067,000	-20,958,000			-69,071,000	-66,611,000			-23,018,000	-21,797,000	-16,255,000	-27,512,000	-34,706,000	-42,075,000		-30,722,000	-35,059,000	-34,891,000		-36,015,000	-38,112,000	-34,883,000																													-15,417,000	-23,459,000		-17,950,000	-12,177,000	-14,111,000	-13,591,000	-18,915,000	-13,823,000	-12,755,000
adjustments to reconcile net loss to net cash from operating activities:
depreciation and amortization	110,000	118,000	151,000	176,000	176,000	125,000	126,000	139,000	144,000	147,000	151,000	144,000	112,000	103,000	108,000	107,000	109,000	112,000	101,000	42,000	37,000	344,000	784,000	900,000	906,000	935,000	908,000	910,000	901,000	912,000	918,000	928,000	925,000	924,000	923,000	918,000	634,000	508,000	511,000	516,000	521,000																																						2,645,000
stock-based compensation	3,078,000	2,835,000	3,444,000	3,195,000	3,043,000	1,537,000	2,801,000	4,859,000	4,302,000	3,212,000	3,898,000	3,815,000	3,415,000	3,268,000	2,648,000	2,832,000	2,772,000	2,228,000	2,712,000	2,786,000	2,851,000	2,680,000	1,904,000	4,258,000	4,432,000	3,479,000	3,562,000	3,766,000	3,411,000	2,847,000	2,877,000	2,898,000	3,074,000	2,258,000	2,580,000	2,403,000	2,231,000	1,730,000	1,930,000	1,957,000	1,835,000	1,430,000	1,672,000	1,788,000	1,953,000	1,497,000	1,494,000	1,840,000	2,250,000	1,693,000	1,750,000	1,869,000	2,109,000	1,590,000	1,592,000	1,595,000	1,718,000	1,353,000	1,432,000	1,450,000	1,472,000	1,520,000	1,333,000	1,320,000	1,305,000	1,196,000	1,280,000	1,356,000	1,442,000	1,719,000	1,419,000	1,583,000	1,779,000	3,096,000	1,600,000	1,671,000	1,559,000	1,662,000	1,761,000
amortization of debt-related costs	681,000					401,000	402,000	525,000	517,000	618,000
accretion of marketable securities purchased at a discount	-562,000	-440,000	-732,000	-1,214,000	-1,326,000	-1,887,000
other non-cash adjustments	-581,000	-163,000	-18,000	-21,000	-1,540,000	331,000	5,591,000	-4,884,000	-226,000	-492,000
changes in operating assets and liabilities:
decrease in accounts receivable	-9,395,000	-50,000	-151,000											12,000	-6,000	3,000	-23,000	9,000	136,000	-58,000	294,000	1,026,000	26,545,000	-741,000	26,397,000	309,000	-51,261,000	-1,190,000	1,534,000	-3,011,000	1,493,000	76,000	343,000	3,271,000	-5,583,000	3,719,000	-1,241,000	-4,253,000	280,000	-277,000	170,000	-839,000	244,000	-146,000	865,000	-168,000	116,000	190,000	319,000	105,000	119,000	-151,000	515,000	-1,145,000	-51,000	4,000	164,000		16,000								-817,000										-536,000		2,832,000
decrease in inventories	5,000	-123,000	10,000
decrease in prepaid expenses and other current assets	-319,000	1,084,000	-358,000										-867,000	154,000	262,000	-1,005,000	273,000	900,000	1,534,000	-644,000	1,095,000					653,000	652,000	-1,939,000	-2,018,000	727,000	558,000	331,000	150,000	23,000	5,716,000			-1,435,000	6,628,000	5,200,000	-4,134,000				1,570,000													589,000	-463,000	-426,000	-565,000	376,000	3,275,000	-232,000	3,285,000				1,784,000	1,582,000			489,000	-372,000	-48,000	-155,000	830,000	-1,017,000	289,000
decrease in other long-term assets	195,000	190,000	191,000	190,000	186,000	639,000	176,000	171,000	166,000	78,000
decrease in accounts payable and other liabilities	-6,899,000		-14,004,000	11,123,000	-21,692,000				-9,108,000				-2,770,000		810,000	-2,139,000	-3,308,000										13,197,000				1,944,000														-1,302,000				-1,876,000				-905,000									-1,927,000	-1,852,000	-348,000	-1,111,000			1,847,000	-6,024,000			2,764,000	-2,787,000			1,124,000	-2,695,000
net cash from operating activities	-14,730,000	-17,233,000	-23,833,000	16,993,000	-43,778,000	-21,491,000	-53,619,000	-48,540,000	-55,130,000	-50,548,000	-41,619,000	-38,117,000	-31,613,000	-21,569,000	-19,439,000	-24,422,000	-23,421,000	-22,828,000	-17,150,000	-21,880,000	-25,159,000	-34,239,000	-40,378,000	-46,298,000	-22,054,000	-24,371,000	190,698,000	-26,900,000	-25,620,000	-27,128,000	-22,181,000	-52,523,000	-46,775,000	-33,711,000	-33,962,000	-32,225,000	-85,496,000	-48,791,000	-35,219,000	-47,878,000	-43,740,000	265,924,000	-25,485,000	-32,178,000	-23,485,000	-4,458,000	-21,190,000	-19,655,000	-30,319,000	-21,741,000	-23,935,000	-21,132,000	-24,271,000	-20,432,000	-25,069,000	-21,957,000	-27,002,000	-22,491,000	-20,218,000	-23,689,000	-21,540,000	-19,413,000	-18,632,000	-22,623,000	-21,700,000	-17,251,000	-19,682,000	-23,929,000	-28,154,000	-19,690,000	-22,707,000	-26,648,000	-26,555,000		-18,660,000	-20,532,000	-20,817,000	-9,932,000	-15,087,000
capital expenditures	0	0	0	0	0	-474,000	-307,000	0		0	-83,000	-139,000	-248,000	-1,246,000	-4,000	0	-76,000	-23,000	-213,000	-947,000	-38,000	-54,000	0	0		0	0	0	-70,000	-37,000	-3,000	-15,000	-40,000	-4,000	-61,000	-71,000	-92,000	-148,000	-16,000	-13,000	-54,000	-246,000	-184,000	-463,000	-17,000	-34,000	-7,000	-11,000	-28,000	-215,000	-268,000	-399,000	-839,000	-113,000	-50,000	-95,000	-234,000	-209,000	-182,000	-308,000	-507,000	-254,000	-316,000	-77,000	-485,000	-66,000	-61,000	-86,000	-156,000	-515,000	-269,000	-524,000	-879,000		-359,000	-620,000	-318,000	-416,000	-822,000
free cash flows	-14,730,000	-17,233,000	-23,833,000	16,993,000	-43,778,000	-21,965,000	-53,926,000	-48,540,000		-50,548,000	-41,702,000	-38,256,000	-31,861,000	-22,815,000	-19,443,000	-24,422,000	-23,497,000	-22,851,000	-17,363,000	-22,827,000	-25,197,000	-34,293,000	-40,378,000	-46,298,000		-24,371,000	190,698,000	-26,900,000	-25,690,000	-27,165,000	-22,184,000	-52,538,000	-46,815,000	-33,715,000	-34,023,000	-32,296,000	-85,588,000	-48,939,000	-35,235,000	-47,891,000	-43,794,000	265,678,000	-25,669,000	-32,641,000	-23,502,000	-4,492,000	-21,197,000	-19,666,000	-30,347,000	-21,956,000	-24,203,000	-21,531,000	-25,110,000	-20,545,000	-25,119,000	-22,052,000	-27,236,000	-22,700,000	-20,400,000	-23,997,000	-22,047,000	-19,667,000	-18,948,000	-22,700,000	-22,185,000	-17,317,000	-19,743,000	-24,015,000	-28,310,000	-20,205,000	-22,976,000	-27,172,000	-27,434,000		-19,019,000	-21,152,000	-21,135,000	-10,348,000	-15,909,000
cash flows from investing activities:
purchases of investments	-105,960,000	-22,170,000	-26,725,000	-25,972,000	-64,971,000	-25,826,000	-42,624,000	-77,073,000	-183,224,000	-102,000	-72,243,000	-122,134,000	-28,864,000	-586,000	-93,192,000	-22,355,000	-17,816,000	-5,381,000	-4,507,000	-2,687,000	-21,686,000	-5,358,000	-16,049,000	-3,926,000	-33,222,000	-145,398,000	-70,281,000	-19,450,000	-87,256,000	-35,512,000	-34,837,000	-2,746,000	-46,892,000	-208,636,000	752,000	916,000	-60,905,000	-89,024,000	-117,212,000	-10,451,000	-208,986,000	-243,892,000	-12,049,000	473,000	-70,978,000	-201,302,000	0	0	-20,651,000	-30,536,000	0	0	-80,954,000	-81,474,000	0	0	-151,776,000	-25,467,000	-18,499,000	-30,231,000	-33,895,000	-149,857,000					0				0				-176,985,000	-10,305,000	-5,692,000		-5,903,000
maturities of investments	35,697,000	27,000,000	78,850,000	41,455,000	105,553,000	80,000,000	96,400,000	65,000,000	73,000,000	52,000,000	33,000,000	47,665,000	41,205,000	26,006,000	16,000,000	8,707,000	13,484,000	11,500,000	4,320,000	17,772,000	4,000,000	38,500,000	71,500,000	82,000,000	76,000,000	36,000,000	39,000,000	12,000,000	79,600,000	94,300,000	91,235,000	50,128,000	53,995,000	72,874,000	86,356,000	55,941,000	103,452,000	145,631,000	151,125,000	72,000,000	75,400,000	120,000,000				30,258,000	20,222,000	526,000	60,438,000	70,500,000	20,502,000	10,780,000	110,843,000	74,780,000	11,686,000	26,949,000	22,435,000	43,705,000	49,314,000	54,568,000	29,041,000	4,990,000	11,051,000	30,025,000	2,575,000		30,371,000				8,019,000				20,862,000	22,559,000	15,564,000		15,821,000
net cash from investing activities	-70,263,000	4,830,000	52,125,000	15,483,000	40,582,000	53,700,000	53,469,000	-12,323,000	-110,224,000	51,898,000	-39,326,000	-74,608,000	12,093,000	24,174,000	-77,196,000	-13,648,000	-4,408,000	6,096,000	-400,000	14,138,000	-17,724,000	44,101,000	215,803,000	78,074,000	42,778,000	-109,398,000	-31,281,000	-7,450,000	-7,726,000	58,751,000	56,395,000	47,367,000	7,063,000	-135,766,000	87,047,000	56,786,000	42,455,000	56,459,000	33,897,000	61,536,000	-133,640,000	-124,138,000	77,768,000	340,000	-70,991,000	-170,716,000	20,506,000	1,223,000	40,568,000	39,771,000	20,240,000	10,426,000	29,107,000	-6,729,000	11,642,000	26,855,000	-129,575,000	18,032,000	30,739,000	26,502,000	-5,318,000	-145,101,000	-810,000	29,968,000	2,099,000	548,000	32,435,000	34,091,000	-55,197,000	5,585,000	13,485,000	77,054,000	63,291,000		-151,061,000	-33,356,000	9,554,000	-9,296,000	9,096,000
cash flows from financing activities:
proceeds from issuance of common stock, net of fees	69,986,000									0	-211,000			-63,000				379,000	19,781,000	-23,000	16,947,000
proceeds from issuance of preferred stock, net of fees	26,548,000					-78,000	-10,000	-15,000	241,425,000
proceeds from issuance of common stock for equity incentive plans	65,000					-25,000	0	1,000	88,000
payments for tax withholding on share-based compensation vesting	-2,843,000	0	0	0	-572,000
repayment of debt borrowings	-5,000,000	-3,000,000	0																			-5,820,000	-210,117,000	-322,000	-321,000	-322,000	-320,000	-322,000	-321,000	-321,000	-13,043,000	-588,000	-581,000	-566,000	-552,000	-626,000	-536,000	-521,000	-507,000	-497,000	-491,000	-480,000	-467,000	-456,000	-456,000	-442,000	-429,000	-419,000	-420,000	-407,000	-394,000	-386,000	-387,000	-375,000	-362,000	-353,000	-353,000	-345,000	-329,000	-2,631,000	-284,000	-271,000	-16,268,000	-30,403,000	-2,916,000	-650,000	-560,000	-541,000	-369,000	-231,000	-219,000	-214,000	-217,000	-211,000	-202,000	-196,000	-206,000	-195,000	-184,000
net cash from financing activities	88,756,000	-2,927,000	0	-45,000,000	-572,000	-104,000	-916,000	-14,000	239,383,000	-1,000	-210,000	188,995,000	-824,000	24,906,000	94,019,000	0	23,284,000	-11,321,000	19,781,000	-23,000	14,272,000	64,150,000	-210,117,000	-425,000	-1,244,000	-322,000	-320,000	-322,000	-1,262,000	-139,000	-356,000	-221,000	-1,528,000	147,845,000	-498,000	3,690,000	-1,104,000	160,000	1,684,000	71,000	-928,000	-471,000	-353,000	-378,000	-830,000	285,665,000	-266,000	-360,000	-1,231,000	-112,000	22,000	-288,000	-1,011,000	36,825,000	407,000	-129,000	-722,000	160,247,000	-328,000	-2,603,000	-232,000	-266,000	-16,268,000	-19,773,000	179,173,000	54,521,000	817,000	22,051,000	14,431,000	-231,000	-218,000	-214,000	-217,000		197,855,000	56,867,000	645,000	37,336,000	3,567,000
net increase in cash, cash equivalents and restricted cash	3,763,000		28,292,000
cash, cash equivalents, and restricted cash at beginning of period	63,326,000		0
cash, cash equivalents, and restricted cash at end of period	67,089,000		28,292,000
supplemental disclosure of cash flow information:
cash paid for interest	1,477,000	1,685,000	1,757,000	1,920,000	2,968,000	3,125,000	3,282,000	3,255,000	3,257,000	3,290,000	3,453,000	1,758,000	1,556,000	1,008,000	647,000	549,000	85,000	492,000	0			461,000	7,323,000	5,911,000	3,658,000	5,968,000	3,633,000	5,912,000	3,698,000	5,995,000	3,744,000	5,952,000	774,000	2,598,000	316,000	2,624,000	332,000	2,644,000	360,000	2,668,000	378,000	2,684,000	402,000	2,772,000	412,000	406,000	459,000	449,000	447,000	460,000	475,000	482,000	480,000	493,000	506,000	513,000	516,000	522,000	540,000	801,000	584,000	596,000	608,000	614,000	606,000	622,000	630,000	641,000	626,000	637,000	651,000	655,000	656,000	661,000	667,000	675,000	662,000	672,000	684,000
supplemental disclosure of non-cash investing and financing activities:
accrued financing costs	313,000							760,000	150,000
increase in accounts payable and other liabilities						9,128,000	8,871,000			-2,654,000	6,113,000							-725,000	1,274,000	-6,289,000	-8,418,000	-35,250,000	-18,251,000	17,395,000	15,137,000				-8,171,000				9,469,000	4,566,000	10,531,000	2,434,000	-24,703,000	8,945,000	12,887,000	1,982,000	3,836,000	3,279,000	6,250,000			-5,321,000	3,895,000			-3,565,000	4,433,000			892,000	-1,570,000	534,000	-851,000	6,541,000	1,464,000	-1,489,000	3,849,000					1,268,000				-3,217,000				2,936,000				1,539,000
purchases of property and equipment						-474,000	-307,000			0	-83,000	-139,000	-248,000	-1,246,000	-4,000	0	-76,000	-23,000	-213,000	-947,000	-38,000	-54,000				0	0	0	-70,000	-37,000	-3,000	-15,000	-40,000	-4,000	-61,000	-71,000	-92,000	-148,000	-16,000	-13,000	-54,000	-246,000	-184,000	-463,000	-17,000	-34,000	-7,000	-11,000	-28,000	-215,000	-268,000	-399,000	-839,000	-113,000	-50,000	-95,000	-234,000	-209,000	-182,000	-308,000	-507,000	-254,000	-316,000	-77,000	-485,000	-66,000	-61,000	-86,000	-156,000	-515,000	-269,000	-524,000	-879,000	-603,000	-359,000	-620,000	-318,000	-416,000	-822,000
proceeds from debt borrowings, net of fees											1,000				-249,000	0	24,148,000													0
other debt financing fees						-1,000
net increase in cash, cash equivalents, and restricted cash
cash, cash equivalents, and restricted cash at beginning of year
cash, cash equivalents, and restricted cash at end of year
supplemental disclosure of noncash investing and financing activities:
right-of-use assets obtained in exchange for operating lease obligations		0
issuance of equity-classified warrants										0	0
accrual of deferred financing costs
conversion of preferred stock to common stock						0	0
amortization/accretion of debt-related costs			402,000	402,000	401,000
net income					-25,295,000																	-5,495,000				-51,138,000
adjustments to reconcile net income to net cash from operating activities:
decrease (increase) in accounts receivable					1,026,000
decrease (increase) in inventories					30,000
decrease (increase) in prepaid expenses and other current assets					1,213,000
net increase in cash and cash equivalents					-3,768,000	32,105,000	-1,066,000	-60,877,000	74,029,000									-28,053,000	2,231,000	-7,765,000	-28,611,000	74,012,000	-34,692,000	31,351,000	19,480,000	-134,091,000				31,484,000			-41,240,000	-21,632,000											-95,306,000				9,018,000				3,825,000					155,788,000	10,193,000	210,000	-27,090,000	-164,780,000	-35,710,000	-12,428,000	159,572,000	37,818,000	13,570,000	32,213,000	-68,920,000	-14,336,000	-9,440,000	50,192,000	36,519,000	-27,783,000				18,108,000
cash and cash equivalents at beginning of period					66,656,000		0	0	22,465,000		0	0	46,345,000		0	0	64,065,000		0	0	126,263,000		0	0	36,112,000		0	0	80,386,000		0	0	61,661,000		0	0	46,600,000		0	0	202,989,000		0	0	137,266,000		0	0	37,499,000		0	0	30,423,000		0	0	186,309,000		0	0	47,208,000		0	0	100,554,000		0	0	85,873,000		0	0	22,938,000		0	0	30,226,000		0
cash and cash equivalents at end of period					62,888,000		-1,066,000	-60,877,000	96,494,000		-81,155,000	76,270,000	26,001,000		-2,616,000	-38,070,000	59,520,000		2,231,000	-7,765,000	97,652,000		-34,692,000	31,351,000	55,592,000		159,097,000	-34,672,000	45,778,000		33,858,000	-5,377,000	20,421,000		52,587,000	28,251,000	2,455,000		362,000	13,729,000	24,681,000		51,930,000	-32,216,000	41,960,000		-950,000	-18,792,000	46,517,000		-3,673,000	-10,994,000	34,248,000		-13,020,000	4,769,000	29,010,000		10,193,000	210,000	20,118,000		-35,710,000	-12,428,000	260,126,000		13,570,000	32,213,000	16,953,000		-9,440,000	50,192,000	59,457,000		28,134,000	2,979,000	19,608,000		-2,424,000
loss on disposal of property and equipment																																		1,000	0			4,000	0	0	12,000				6,000																		62,000					2,000	2,000									0	0
increase in accounts receivable						-578,000	-275,000	-1,094,000	-516,000		367,000	-423,000	-234,000																																																-87,000				-737,000
repurchase of common stock										0	0	0	-824,000	0	0	0	-864,000	0	0	0	-2,675,000	0	0	-103,000	-923,000	0	0	0	-941,000	0	0	0	-972,000	0	0	0	-1,679,000	0	0	0	-621,000	0	0	0	-357,000	0	0	0	-887,000	0	0	0	-873,000	0	0	0	-285,000	0	0	0	-108,000	0	0	0	-149,000	0
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
right-of-use assets obtained in exchange for operating lease liability
issuance of treasury stock														0	0	0	6,321,000
increase in inventories							-51,000	-71,000	-133,000	-45,000
increase in prepaid expenses and other current assets							969,000	-666,000	-1,879,000		1,708,000												-1,867,000	-1,266,000	-2,875,000												-6,498,000						-3,802,000				1,405,000	-772,000	-1,934,000		-573,000	1,754,000	-2,089,000		-2,422,000	-1,439,000	-1,395,000										800,000
repurchase of common stock for equity incentive plans							0	0	-1,730,000
other								0	-400,000
proceeds (repayment) of debt borrowings, net of fees
net decrease in cash and cash equivalents										1,349,000			-20,344,000		-2,616,000	-38,070,000	-4,545,000											-34,672,000	-34,608,000							28,251,000	-44,145,000		362,000	13,729,000	-178,308,000		51,930,000				-950,000				-3,673,000				-13,020,000	4,769,000	-157,299,000																			2,979,000	-10,618,000
right-of-use asset obtained in exchange for operating lease liability
amortization of debt issuance costs												273,000	265,000	345,000	217,000	154,000	25,000	8,000	17,000	15,000	14,000	18,000	269,000	364,000	362,000	378,000	379,000	362,000	346,000	379,000	365,000	285,000	307,000	187,000	158,000	144,000	110,000	138,000	139,000	125,000	125,000	140,000	139,000	179,000	62,000
increase in inventory																														75,000	-2,613,000	-30,000	-164,000				-236,000
decrease in operating lease right-of-use-assets												161,000	400,000
issuance of equity classified warrants														332,000	0	0	698,000
recognition of exit fee liability related to debt borrowings														0	0	0	1,500,000
gain on sale of xermelo
impairment loss on building
gain on debt extinguishments
decrease in inventory																						0	91,000	158,000	96,000	233,000	-199,000	329,000	74,000
decrease in other assets														327,000	-91,000	213,000	207,000	202,000	198,000	335,000	-74,000	110,000	107,000	105,000	102,000	99,000	144,000	95,000	91,000				-3,000	1,000	-1,000	0	33,000						-56,000	-20,000	-393,000		12,000	40,000	11,000	-71,000	18,000	23,000	21,000	26,000	22,000	24,000	24,000	76,000	-28,000	51,000	315,000	-122,000	-145,000	25,000	24,000	26,000	27,000	25,000	26,000	53,000	1,000			27,000	27,000	83,000	-28,000	38,000	35,000
proceeds from xermelo sale																						0
proceeds from disposal of property and equipment																																										0	1,000	330,000	4,000	362,000	291,000	708,000	809,000	22,000	6,000	45,000	57,000	78,000	6,000			3,000	106,000	2,473,000	43,000	20,000	15,000	20,000	9,000	-3,000	73,000	1,000	36,000					0	0			0	0
proceeds (repayment) of debt borrowings
right-of-use assets obtained in exchange for lease obligations
liabilities assumed by tersera from the xermelo sale																						257,000
common stock issued in satisfaction of convertible debt exchanges																						1,618,000
supplemental disclosure of non-cash activities:
right-of-use asset																		0	0	4,000	1,700,000
deferred tax benefit																										0								-4,009,000	0	0	-8,652,000
impairment loss on intangible asset																										0
decrease in deferred revenue																										-61,000	-25,394,000			1,211,000	-211,000	-6,195,000	-18,801,000		-16,226,000	-6,413,000	-14,384,000		-19,408,000	-19,747,000	-12,187,000		-475,000	-93,000	-278,000			-26,000	-18,000			-5,000	-5,000					-45,000	26,000	-47,000	-29,000	-633,000	333,000	-62,000	-366,000	-139,000	-193,000	-1,835,000	-2,563,000	-998,000	-3,653,000	-3,325,000	-6,296,000		-5,348,000	-8,173,000	-3,500,000
gain on sale of xermelo assets
impairment loss on buildings
loss on debt extinguishments
gain on disposal of property and equipment																																										0	12,000			-820,000	-78,000	-469,000	-264,000											16,000	-31,000
increase in deferred revenue																													9,000																	833,000																																-1,785,000	-11,353,000
increase in fair value of symphony icon, inc. purchase liability																																		0	0	0	2,101,000	0	-2,146,000	478,000	965,000	782,000	3,404,000	-12,000	1,753,000	910,000	-1,072,000	448,000	1,142,000	-5,289,000	1,338,000	477,000	1,264,000	-200,000	5,844,000	2,162,000	2,081,000
common stock issued in satisfaction of symphony icon payment obligation																																		0	0	0	10,499,000
proceeds from issuance of common stock																															158,000	367,000	25,000		54,000	4,316,000	1,111,000		2,191,000	568,000	184,000						163,000	86,000	76,000		527,000	98,000	249,000		779,000	224,000	52,000		1,000	28,000	160,000		0	3,000	181,488,000												851,000	37,531,000	3,751,000
unrealized gain on investments																											-50,000	53,000	45,000	59,000	147,000			-159,000	151,000	50,000	-69,000	-273,000	-258,000	39,000	516,000		-40,000	75,000	86,000			-5,000	8,000	-36,000	7,000	-11,000	19,000			37,000	-78,000	-13,000	-37,000	31,000	35,000									-38,000	3,263,000				-153,000			-12,000	38,000
adjustments to reconcile consolidated net loss to net cash from operating activities:
unrealized loss on investments																																	-172,000																																			4,000	-5,000				-2,328,000				9,000
consolidated net loss																																										86,750,000	-35,282,000	-28,074,000	-28,076,000	-2,933,000	-40,498,000	-26,028,000	-30,835,000	-17,414,000	-31,658,000	-29,080,000	-25,974,000	-24,873,000	-29,539,000	-25,931,000	-29,868,000	-33,845,000	-26,103,000	-26,638,000	-29,629,000	-22,999,000	-27,513,000	-25,193,000	-26,070,000	-22,770,000	-22,668,000
impairment of assets
other financing activities																																										9,000	0	78,000	-17,000		0			85,000					-10,000	0	-136,000
(increase) in inventory																																			-1,338,000
increase in other assets																																						-7,000
impairment of fixed assets																																															13,102,000	0	242,000									-96,000	0	0	800,000	951,000				-9,000	0	39,000	406,000
depreciation																																											60,000	246,000	355,000		526,000	554,000	644,000	669,000	576,000	825,000	793,000	916,000	1,055,000	1,094,000	1,125,000	1,135,000	1,181,000	1,264,000	1,307,000	1,312,000	1,337,000	1,365,000	1,380,000	1,399,000	1,443,000	1,545,000	1,772,000	1,872,000	1,929,000	2,070,000	2,058,000	2,124,000	2,223,000	2,447,000	2,468,000
common stock issued in satisfaction of symphony icon base payment obligation																																																						0
amortization of symphony icon, inc. purchase option																																																														0	2,600,000	679,000	678,000		535,000	536,000	535,000			536,000	535,000
net gain on auction rate securities ("ars") and ars rights
acquisition of symphony icon, inc., net of cash acquired																																																														0
proceeds from debt borrowings																																																														0	0	10,627,000	750,000	0	1,200,000	22,592,000	14,800,000
cash received related to income taxes
intangible assets acquired with long-term liabilities																																																														87,114,000
change in fair value of symphony icon, inc. purchase liability																																																										1,568,000	2,336,000	1,804,000	1,058,000
decrease in receivables
purchases of investments held by symphony icon, inc.																																																																		-2,750,000								0	0
maturities of investments held by symphony icon, inc.																																																																		3,016,000	3,552,000	4,097,000	4,778,000	4,537,000	5,735,000	6,539,000	3,245,000	2,904,000
net gain on auction rate securities (“ars”) and ars rights
loss on auction rate securities																																																																	-2,238,000
loss on ars rights																																																														0	0	7,575,000	2,150,000	947,000
gain on auction rate securities																																																															0
amortization of symphony icon purchase option																																																																						535,000
purchase of short-term investments
maturities of short-term investments																																																																					100,000				100,773,000
proceeds from issuance of common stock to invus, l.p., net of fees
proceeds from issuance of common stock to symphony holdings, llc, net of fees																																																																										-1,000	-20,000
proceeds from purchase of noncontrolling interest by preferred shareholders of symphony icon, inc.
common stock issued for purchase option in conjunction with symphony icon financing
loss on investments
proceeds from exercise of stock options																																																																											3,000
gain on long-term investments
gain on ars rights																																																																				460,000	-558,000
net loss attributable to lexicon pharmaceuticals, inc.																																																																					-21,560,000
loss attributable to noncontrolling interest																																																																					-2,777,000	-4,013,000	-4,939,000	-6,148,000	-4,924,000	-4,269,000	-3,867,000
impairment of long-term investments																																																																					41,000
(increase) decrease in accounts receivable																																																																					-680,000				519,000
purchases of short-term investments																																																																					-59,955,000				-39,848,000
amortization of intangible assets, other than goodwill																																																																														0	40,000
sale of short-term investments
deferred stock compensation, net of reversals
issuance of common stock to repay note and accrued interest
proceeds from issuance of common stock to invus, l. p., net of fees
proceeds from purchase of noncontrolling interest by preferred shareholders of symphony icon, inc., net of fees
common stock issued for purchase option in conjunction with symphony icon, inc. financing																																																																											0
(increase) decrease in prepaid expenses and other current assets
(increase) decrease in other assets																																																																									22,000
retirement of property and equipment																																																																									288,000	163,000	183,000	599,000	219,000	9,000	10,000
adjustments to reconcile net loss to net cash from (used in) operating activities:
net cash from (used in) operating activities
net cash from (used in) investing activities
net cash from (used in) financing activities
unrealized gain (loss) on investments
decrease in restricted cash
repayment of other long-term liabilities
reversal of deferred stock compensation, in connection with stock options

Lexicon Pharmaceuticals, Inc(NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc
(NASDAQ:LXRX)